Adaptive Solriamfetol Therapy for Specialized Environments
Legal Citation
Summary of the Inventive Concept
The inventive concept provides novel methods and systems for administering solriamfetol therapy to subjects with impaired renal function in unique operational environments, such as disaster relief, high-security, extreme weather, remote, or military settings.
Background and Problem Solved
The original patent disclosed methods for decreasing adverse effects associated with solriamfetol therapy in subjects with impaired renal function. However, these methods did not address the challenges of administering solriamfetol therapy in specialized environments, where standard dosing regimens may not be effective or safe. The new inventive concept addresses this limitation by providing adaptive dosing schemes and systems tailored to these unique environments.
Detailed Description of the Inventive Concept
The inventive concept comprises four primary aspects: (1) a method for providing solriamfetol therapy in a disaster relief setting, involving reduced dosing for subjects with severe renal impairment; (2) a system for treating excessive daytime sleepiness in high-security environments, featuring a secure dosing regimen and monitoring system; (3) a method for adjusting solriamfetol dosing in extreme weather conditions, considering temperature-related effects; and (4) a kit and method for providing solriamfetol therapy in remote or isolated areas, utilizing portable dosing devices and customized dosing regimens. Additionally, the inventive concept includes a method for providing solriamfetol therapy in military or combat settings, taking into account the subject's level of physical activity and environmental conditions.
Novelty and Inventive Step
The new claims introduce novel adaptations of solriamfetol therapy for specialized environments, which are not obvious from the original patent. The inventive concept's value lies in its tailored approaches to addressing the unique challenges of these environments, providing safer and more effective treatment options for subjects with impaired renal function.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include adapting the dosing regimens for use in other specialized environments, such as space exploration or high-altitude settings. Variations of the system for high-security environments could incorporate additional security features, such as biometric authentication or secure data transmission.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in various industries, including disaster relief, healthcare, and national defense. The adaptive solriamfetol therapy methods and systems could be marketed as specialized solutions for unique operational environments, providing a competitive advantage in these niche markets.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical therapeutics, specifically neurological treatment methods for sleep disorders and renal impairment management, with expertise in drug dosing strategies and patient-specific treatment protocols
Person of Ordinary Skill (PHOSITA) Profile
A medical professional with advanced training in clinical pharmacology, specializing in dosage optimization for patients with complex medical conditions, familiar with adaptive drug administration techniques and patient-specific treatment modifications
Obviousness Rationale
A person having ordinary skill would recognize that the source patent's fundamental solriamfetol dosing methodology for renal impairment provides a clear framework for contextual adaptation across specialized environments. The PTD's variations represent predictable extensions of the original patent's core therapeutic approach, applying known clinical dosing principles to specific operational contexts. The modifications demonstrate standard clinical reasoning for drug administration in variable patient scenarios.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,528 |
|---|---|
| Title | Methods of providing solriamfetol therapy to subjects with impaired renal function |
| Assignee(s) | AXSOME MALTA LTD. |